NCT05102552View on ClinicalTrials.gov

Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

March 25, 2022

Study Completion Date

August 15, 2022

Conditions
Healthy Volunteer
Interventions
DRUG

SPN-817, Treatment B

SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

DRUG

SPN-817, Treatment C

SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

DRUG

BIS-001, Treatment A

BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

Trial Locations (1)

3004

Nucleus Network, Melbourne

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT05102552 - Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter